|
AU723355B2
(en)
*
|
1996-05-23 |
2000-08-24 |
Scripps Research Institute, The |
MHC class II antigen presenting systems and methods for activating CD4+ T cells
|
|
US6291430B1
(en)
*
|
1997-09-12 |
2001-09-18 |
Ludwig Institute For Cancer Research |
Mage-3 peptides presented by HLA class II molecules
|
|
JP4601166B2
(ja)
|
1998-05-11 |
2010-12-22 |
ミルテニィ バイオテック ゲーエムベーハー |
抗原特異的ｔ細胞の直接的選択方法
|
|
US6230662B1
(en)
|
1998-06-22 |
2001-05-15 |
Theresa Miale |
Animal lift and transport apparatus and method for using the same
|
|
EP1104456A1
(en)
*
|
1998-08-10 |
2001-06-06 |
Chiron Corporation |
Engineered antigen-presenting cells expressing an array of antigens and uses thereof
|
|
US7807377B2
(en)
|
1998-10-20 |
2010-10-05 |
Salvatore Albani |
Method of isolating antigen-specific T cells employing artificial antigen presenting cells
|
|
JP2002527467A
(ja)
*
|
1998-10-20 |
2002-08-27 |
サルバトーレ・アルバーニ |
抗原特異的ｔ細胞の単離、定量、特徴づけおよび調節方法
|
|
US6225443B1
(en)
*
|
1999-05-19 |
2001-05-01 |
Wisconsin Alumni Research Foundation |
Cytotoxic T lymphocyte epitopes of the major outer membrane protein of chlamydia trachomatis
|
|
US7521202B2
(en)
|
1999-12-17 |
2009-04-21 |
The Board Of Regents Of The University Of Oklahoma |
Method and apparatus for the production of soluble MHC antigens and uses thereof
|
|
DE10009341A1
(de)
*
|
2000-02-22 |
2001-09-06 |
Florian Kern |
Verfahren zur antigen-spezifischen Stimulation von T-Lymphozyten
|
|
US7572631B2
(en)
|
2000-02-24 |
2009-08-11 |
Invitrogen Corporation |
Activation and expansion of T cells
|
|
US7541184B2
(en)
|
2000-02-24 |
2009-06-02 |
Invitrogen Corporation |
Activation and expansion of cells
|
|
WO2001080833A1
(en)
*
|
2000-04-20 |
2001-11-01 |
Salvatore Albani |
Methods for isolation, quantification, characterization and modulation of antigen-specific t cells
|
|
JP2004536554A
(ja)
|
2000-10-10 |
2004-12-09 |
ザ ボード オブ リージェンツ オブ ザ ユニヴァーシティー オブ オクラホマ |
Ｍｈｃ陽性細胞からの比較リガンドマッピング
|
|
US20070026433A1
(en)
|
2001-03-09 |
2007-02-01 |
Hildebrand William H |
Epitope testing using soluble HLA
|
|
WO2002056908A2
(en)
*
|
2001-01-16 |
2002-07-25 |
Hildebrand William H |
Artificial antigen-presenting cells
|
|
AU2002255532A1
(en)
*
|
2001-02-13 |
2002-10-15 |
Joseph D. Mosca |
Biological carriers for induction of immune responses
|
|
WO2002065992A2
(en)
*
|
2001-02-20 |
2002-08-29 |
Ortho-Mcneil Pharmaceutical, Inc. |
A cell therapy method for the treatment of tumors
|
|
US20040071671A1
(en)
*
|
2001-02-20 |
2004-04-15 |
Leturcq Didier J. |
Cell therapy method for the treatment of tumors
|
|
FR2824567B1
(fr)
*
|
2001-05-11 |
2003-08-08 |
Inst Nat Sante Rech Med |
Procede d'obtention de lymphocytes tr1 regulateurs specifiques d'antigene
|
|
AU2003202908A1
(en)
*
|
2002-01-03 |
2003-07-24 |
The Trustees Of The University Of Pennsylvania |
Activation and expansion of t-cells using an engineered multivalent signaling platform
|
|
US7745140B2
(en)
*
|
2002-01-03 |
2010-06-29 |
The Trustees Of The University Of Pennsylvania |
Activation and expansion of T-cells using an engineered multivalent signaling platform as a research tool
|
|
US7638326B2
(en)
|
2002-01-03 |
2009-12-29 |
The Trustees Of The University Of Pennsylvania |
Activation and expansion of T-cells using an engineered multivalent signaling platform
|
|
US20040072262A1
(en)
*
|
2002-10-11 |
2004-04-15 |
Montero-Julian Felix A. |
Methods and systems for detecting MHC class I binding peptides
|
|
DK1408106T3
(da)
*
|
2002-10-11 |
2007-06-11 |
Sentoclone Ab |
Cancer immunterapi
|
|
US7435592B2
(en)
|
2003-05-13 |
2008-10-14 |
Immunovative Therapies, Ltd. |
Compositions for allogeneic cell therapy
|
|
JP2007511760A
(ja)
*
|
2003-11-03 |
2007-05-10 |
ベックマン コールター インコーポレーティッド |
Ｍｈｃ結合ペプチドを検出するための溶液ベースの方法
|
|
SI2573166T1
(sl)
|
2004-02-26 |
2016-09-30 |
Immunovative Therapies, Ltd. |
Metode za pripravo T-celic za celično terapijo
|
|
US7592431B2
(en)
|
2004-02-26 |
2009-09-22 |
Immunovative Therapies, Ltd. |
Biodegradable T-cell Activation device
|
|
EP1766393A4
(en)
*
|
2004-05-07 |
2008-06-18 |
Beckman Coulter Inc |
MHC-BRIDGE SYSTEM FOR DETECTION OF THE CTL-MEDIATED LYSE OF ANTIGEN-PRESENTING CELLS
|
|
CA2568344C
(en)
|
2004-05-27 |
2016-01-19 |
The Trustees Of The University Of Pennsylvania |
Novel artificial antigen presenting cells and uses therefor
|
|
EP1781313A4
(en)
*
|
2004-06-17 |
2009-08-26 |
Beckman Coulter Inc |
MYCOBACTERIUM TUBERCULOSIS EPITOPES AND METHODS OF USE
|
|
EP1712615A1
(en)
*
|
2005-04-15 |
2006-10-18 |
Txcell |
In vitro production of a cell population using feeder cells
|
|
KR101510065B1
(ko)
|
2005-06-08 |
2015-04-07 |
다나-파버 캔서 인스티튜트 인크. |
예정 세포사 1(ｐｄ-1) 경로를 억제함으로써 지속 감염 및 암을 치료하기 위한 방법 및 조성물
|
|
US20100080792A1
(en)
*
|
2005-06-16 |
2010-04-01 |
Dorothee Herlyn |
Method for Identifying a MHC Class II-Dependent Tumor-Associated T Helper Cell Antigen
|
|
US8101173B2
(en)
|
2005-12-21 |
2012-01-24 |
Sentoclone International Ab |
Method for treating urinary bladder cancer
|
|
US8211425B2
(en)
|
2005-12-21 |
2012-07-03 |
Sentoclone International Ab |
Method for treating disseminated cancer
|
|
AU2006328945B2
(en)
|
2005-12-21 |
2011-06-30 |
Sentoclone International Ab |
Method for treating malignant melanoma
|
|
AU2006328943B2
(en)
|
2005-12-21 |
2011-07-21 |
Sentoclone International Ab |
Improved method for expansion of tumour-reactive T-lymphocytes for immunotherapy of patients with cancer
|
|
US7993638B2
(en)
|
2006-03-01 |
2011-08-09 |
Janssen Pharmaceutica Nv |
Cancer treatment combining lymphodepleting agent with CTLs and cytokines
|
|
CA2665568C
(en)
|
2006-10-04 |
2018-01-09 |
Janssen Pharmaceutica, N.V. |
Preparation of inactivated artificial antigen presenting cells and their use in cell therapies
|
|
CA2947292C
(en)
*
|
2006-12-27 |
2019-07-23 |
Emory University |
Compositions and methods for the treatment of infections and tumors
|
|
US20120034155A1
(en)
*
|
2010-08-03 |
2012-02-09 |
Searete Llc, A Limited Liability Corporation Of The State Of Delaware |
Artificial cells
|
|
EP2370593B1
(en)
*
|
2008-11-28 |
2016-03-30 |
Emory University |
Methods for determining the efficacy of pd-1 antagonists
|
|
US8075895B2
(en)
|
2009-09-22 |
2011-12-13 |
Janssen Pharmaceutica N.V. |
Identification of antigenic peptides from multiple myeloma cells
|
|
EP2404618A1
(en)
|
2010-07-07 |
2012-01-11 |
Stichting Katholieke Universiteit meer in het bijzonder Radboud Universiteit Nijmegen |
Immunomodulatory protein constructs with a helical polymeric backbone.
|
|
EP2601957B1
(en)
*
|
2010-08-06 |
2019-04-10 |
Canine-Lab. Inc. |
Immunological function enhancing agent
|
|
KR102202460B1
(ko)
|
2011-05-03 |
2021-01-14 |
이뮤노베이티브 테라피스, 엘티디. |
생세포를 포함하는 생물학적 약물을 처리하기 위한 방법
|
|
PH12013502252B1
(en)
|
2011-05-03 |
2018-09-21 |
Immunovative Therapies Ltd |
Induction of il-12 using immunotherapy
|
|
US9260696B2
(en)
|
2012-04-24 |
2016-02-16 |
Dan S. Kaufman |
Method for developing natural killer cells from stem cells
|
|
EP3974520A1
(en)
|
2013-05-14 |
2022-03-30 |
Board of Regents, The University of Texas System |
Human application of engineered chimeric antigen receptor (car) t-cells
|
|
KR102467982B1
(ko)
|
2013-12-16 |
2022-11-16 |
더 유나이티드 스테이츠 오브 어메리카, 애즈 리프리젠티드 바이 더 세크러테리, 디파트먼트 오브 헬쓰 앤드 휴먼 서비씨즈 |
Vlp-레플리콘을 이용한 클래스 ii mhc 항원의 전달에 의한 암 면역요법
|
|
CA3190002A1
(en)
|
2014-02-14 |
2015-08-20 |
Board Of Regents, The University Of Texas System |
Chimeric antigen receptors and methods of making
|
|
WO2015148960A1
(en)
|
2014-03-28 |
2015-10-01 |
The Board Of Regents Of The University Of Oklahoma |
Compositions comprising soluble hla/m. tuberculosis-specific ligand complexes and methods of production and use thereof
|
|
US20170158749A1
(en)
|
2014-04-23 |
2017-06-08 |
Board Of Regents, The University Of Texas System |
Chimeric antigen receptors (car) and methods for making and using the same
|
|
WO2015164740A1
(en)
|
2014-04-24 |
2015-10-29 |
Board Of Regents, The University Of Texas System |
Application of induced pluripotent stem cells to generate adoptive cell therapy products
|
|
KR20170075785A
(ko)
|
2014-11-05 |
2017-07-03 |
보드 오브 리전츠, 더 유니버시티 오브 텍사스 시스템 |
유전자 변형된 면역 효과기 세포 및 면역 효과기 세포의 증식용 가공된 세포
|
|
WO2016073629A1
(en)
|
2014-11-05 |
2016-05-12 |
Board Of Regents, The University Of Texas System |
Chimeric antigen receptors (car) to selectively target protein complexes
|
|
FR3031519B1
(fr)
|
2015-01-14 |
2016-12-30 |
Arkema France |
Composition a base de terpolymere electroactif
|
|
AU2016232280B2
(en)
*
|
2015-03-16 |
2018-05-31 |
Helmholtz Zentrum München-Deutsches Forschungszentrum Für Gesundheit Und Umwelt (Gmbh) |
Method of detecting new immunogenic T cell epitopes and isolating new antigen-specific T cell receptors by means of an MHC cell library
|
|
EP3368075B1
(en)
|
2015-10-27 |
2020-01-29 |
Board of Regents, The University of Texas System |
Chimeric antigen receptor molecules and uses thereof
|
|
EP3468994A1
(en)
|
2016-06-08 |
2019-04-17 |
Intrexon Corporation |
Cd33 specific chimeric antigen receptors
|
|
WO2018023100A2
(en)
|
2016-07-29 |
2018-02-01 |
Juno Therapeutics, Inc. |
Anti-idiotypic antibodies and related methods
|
|
WO2018089423A1
(en)
|
2016-11-09 |
2018-05-17 |
Musc Foundation For Research Development |
Cd38-nad+ regulated metabolic axis in anti-tumor immunotherapy
|
|
CA3049652A1
(en)
|
2017-01-10 |
2018-07-19 |
Intrexon Corporation |
Modulating expression of polypeptides via new gene switch expression systems
|
|
US11285196B2
(en)
|
2017-03-13 |
2022-03-29 |
Eslam Abbas Baseuny |
Multivalent biologic constructs for inducing a therapeutic modulation of cellular response and uses thereof
|
|
AU2018254442B2
(en)
|
2017-04-18 |
2024-03-28 |
FUJIFILM Cellular Dynamics, Inc. |
Antigen-specific immune effector cells
|
|
AU2018281316B2
(en)
|
2017-06-07 |
2024-05-30 |
Precigen, Inc. |
Expression of novel cell tags
|
|
CA3081336A1
(en)
|
2017-10-12 |
2019-04-18 |
Gregory LIZEE |
T cell receptors for immunotherapy
|
|
WO2019165121A1
(en)
|
2018-02-21 |
2019-08-29 |
Board Of Regents, The University Of Texas System |
Methods for activation and expansion of natural killer cells and uses therof
|
|
AU2019386140A1
(en)
|
2018-11-28 |
2021-06-24 |
Board Of Regents, The University Of Texas System |
Multiplex genome editing of immune cells to enhance functionality and resistance to suppressive environment
|
|
WO2020112493A1
(en)
|
2018-11-29 |
2020-06-04 |
Board Of Regents, The University Of Texas System |
Methods for ex vivo expansion of natural killer cells and use thereof
|
|
AU2020379848A1
(en)
|
2019-11-06 |
2022-05-19 |
Baylor College Of Medicine |
Method for producing cytotoxic effector memory T cells for T-cell treatment of cancer
|
|
WO2021163191A1
(en)
|
2020-02-10 |
2021-08-19 |
Board Of Regents, The University Of Texas System |
Methods for rapid cloning and expression of hla class i cells
|
|
IL298558A
(en)
|
2020-05-27 |
2023-01-01 |
Antion Biosciences Sa |
Adapter molecules redirect CAR T cells to the antigen of interest
|
|
US12275766B2
(en)
|
2020-12-23 |
2025-04-15 |
Janssen Biotech, Inc. |
Neoantigen peptide mimics
|
|
WO2023211972A1
(en)
|
2022-04-28 |
2023-11-02 |
Medical University Of South Carolina |
Chimeric antigen receptor modified regulatory t cells for treating cancer
|